{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.6","upperLimit":"474.3","value":"280.4"},{"groupId":"OG001","lowerLimit":"75.7","upperLimit":"215.3","value":"145.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"Number of days between the first day of the first cycle to best M-protein response, at least Minimal Response or higher (Partial Response, Very Good Partial Response, near Complete Response, Complete Response).","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle\n\nLenalidomide 25mg: Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle","id":"OG000","title":"Lenalidomide 25mg"},{"description":"Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle\n\nLenalidomide 15mg: Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.","id":"OG001","title":"Lenalidomide 15mg"}],"paramType":"MEAN","populationDescription":"33","reportingStatus":"POSTED","timeFrame":"Data was collected for each subject for the duration of the participation in the study, ranging between 75 to 475 days.","title":"Duration Until Best Response (at Least MR or Minimal Response)","type":"PRIMARY","unitOfMeasure":"Days"}